Firazyr — United Healthcare
Hereditary angioedema (HAE)
Initial criteria
- Diagnosis of hereditary angioedema (HAE)
- Prescribed for the treatment of acute HAE attacks
- Not used in combination with other products indicated for the acute treatment of HAE attacks (e.g., Berinert, Kalbitor, or Ruconest)
Approval duration
12 months